Tioma Therapeutics, an oncology treatment developer, previously known as Vasculox, has secured funding from backers including Novo, GlaxoSmithKline and Roche.
US-based cancer treatment startup Tioma Therapeutics raised $86m yesterday in a series A round featuring corporate venturing subsidiaries of pharmaceutical companies Novo, Roche and GlaxoSmithKline.
Novo Ventures, Roche Venture Fund and SR One co-led the round with venture capital firm RiverVest Venture Partners. Tioma began raising the series A funding in June 2015, according to a regulatory filing.
Founded as Vasculox, Tioma is developing antibodies to treat solid and hematologic cancers, and will use the money to advance its lead…
